During the last two decades tremendous progress in technical development such as 'high through-put screening' and biotechnology procedures resulted in a greater number of new chemical entities available for clinical development. At the same time, the demands on documentation and quality of clinical research data requested by health authorities world wide, increased expenditure for clinical research budgets.
The financial pressure regarding the research budgets of pharmaceutical- and biotechnology companies entails a need for these companies to effectively optimise their limited budgets. In the future, strategies will be needed to assess tolerability, pharmacokinetics and efficacy in humans earlier, faster and with maximum cost effectiveness in order to filter out the compounds with the highest marketability. Fast recruitment and availability of patients for clinical trials as scheduled is of extreme importance. It is well known to all insiders of the clinical research business, that in Western European countries and USA qualified trial centres - in general university centres or CROs having their own clinic - are no longer able to conduct the amount of existing research projects within the desired timeframes. One of the central problems is patient recruitment within a desired time frame.
INNOPHAR
Innovative Pharma Research Eastern Europe GmbH (IPR-EE) and its subcontractors Pharm PlanNet - Ucraine Clinic Ltd (PPN-UA) and
INNOPHAR
Innovative Pharma Research Moldova (IPR-MD) can offer you cost effective and time saving solutions to investigate safety, pharmacokinetics and first efficacy in man, or pharmacokinetics in special patient populations.
PPN-UA, is the first private clinic in Ukraine, specialised exclusively in the conduction of clinical research and combines professional CRO skills with academic expertise in collaboration with members of the Bukovinian State Medical University.
IPR-MD is located at the National Institute of Cardiology and is operated in collaboration with members of the Medical University of Chisinau.
In both countries IPR-EE and the local sites have good connections to national health authorities